CWCunwei Wang

Cunwei Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cunwei Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Chengzhe Yang

    Department of Oral and Maxillofacial Surgery, Qilu Hospital of Shandong University, Jinan, China

    1 shared publication
  • Fenghe Zhang

    Department of Oral and Maxillofacial Surgery, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, School and Hospital of Stomatology, Cheeloo College of Medicine

    1 shared publication
  • Limei Wang

    School of Life Science and Technology Wuhan Polytechnic University Wuhan 430023 China

    1 shared publication
  • Pishan Yang

    Department of Periodontology, School of Stomatology, Shandong University, 44-1 West Wen Hua Road, Jinan, 250012, Shandong, People's Republic of China.

    1 shared publication
  • Ruolin Wang

    Department of Periodontology, School of Stomatology, Shandong University, 44-1 West Wen Hua Road, Jinan, 250012, Shandong, People's Republic of China

    1 shared publication
  • Xiuyin Wu

    Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan, 250012, Shandong, China

    1 shared publication

Latest Publications

  • Open Access

    BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma

    by Limei Wang, Xiuyin Wu, Ruolin Wang, Chengzhe Yang, Zhi Li, Cunwei Wang, Fenghe Zhang, Pishan Yang

    Bromodomain-containing protein 4 (BRD4) inhibition is a new therapeutic strategy for many malignancies. In this study, we aimed to explore the effect of BRD4 inhibition by JQ1 on in vitro cell growth, migration and invasion of salivary adenoid cystic carcinoma (SACC). The human normal epithelial cells and SACC cells (ACC-LM and ACC-83) were treated with JQ1 at concentrations of 0, 0.1, 0.5 or 1 μM. Cell Counting Kit-8 (CCK-8) assay was performed to evaluate cell proliferation. Cell apoptosis and cell cycle distribution was evaluated by Flow cytometry. Immunofluorescence staining was used to examine the expression of BRD4 in SACC cells. The quantitative real-time polymerase chain reaction (qRT-PCR) assay and western blot assay were performed to examine messenger RNA (mRNA) and protein levels in SACC cells. Wound-healing assay and transwell assay were used to evaluate the activities of migration and invasion of SACC cells. JQ1 exhibits no adverse effects on proliferation, cell cycle and cell apoptosis of the normal human epithelial cells, while suppressed proliferation and cell cycle, and induced apoptosis of SACC cells, down-regulated the mRNA and protein levels of BRD4 in SACC cells, meanwhile reduced protein expressions of c-myc and BCL-2, two known target genes of BRD4. Moreover, JQ1 inhibited SACC cell migration and invasion by regulating key epithelial–mesenchymal transition (EMT) characteristics including E-cadherin, Vimentin and Twist. BRD4 is an important transcription factor in SACC and BRD4 inhibition by JQ1 may be a new strategy for SACC treatment.